These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 38517596)

  • 41. Management of Rectal Cancer Without Radical Resection.
    Beets GL; Figueiredo NF; Beets-Tan RG
    Annu Rev Med; 2017 Jan; 68():169-182. PubMed ID: 27618750
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patient and multidisciplinary team perspectives on watch and wait in rectal cancer.
    Mohan H; Rabie M; Walsh C; Harji D; Sutton P; Geh I; Jackson I; Helbren E; Evans M; Jenkins JT
    Colorectal Dis; 2023 Jul; 25(7):1489-1497. PubMed ID: 37477408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oncological Outcomes and Hospital Costs of the Treatment in Patients With Rectal Cancer: Watch-and-Wait Policy and Standard Surgical Treatment.
    Hupkens BJP; Breukink SO; Stoot JHMB; Toebes RE; van der Sande ME; Melenhorst J; Beets GL; Dirksen CD
    Dis Colon Rectum; 2020 May; 63(5):598-605. PubMed ID: 32032202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Organ Preservation in Rectal Cancer: An Overview of the Dutch Perspective and Recent Developments.
    Verrijssen AE; Ketelaers SHJ; Rutten HJT; Theuws J; Burger JWA; Cnossen JS
    Clin Oncol (R Coll Radiol); 2023 Feb; 35(2):107-116. PubMed ID: 36253320
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Transition of treatment strategy for locally advanced rectal cancer towards "watch and wait"].
    Xiao WW; Chen G
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jun; 22(6):514-520. PubMed ID: 31238631
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
    Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
    [No Abstract]   [Full Text] [Related]  

  • 47. A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol.
    Vatandoust S; Wattchow D; Sposato L; Michael MZ; Leung J; Gormly K; Chen G; Symonds EL; Tie J; Papanicolas LE; Woods S; Gebski V; Mead K; Kuruni A; Karapetis CS
    BMC Cancer; 2022 Mar; 22(1):222. PubMed ID: 35232427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term Outcome of an Organ Preservation Program After Neoadjuvant Treatment for Rectal Cancer.
    Martens MH; Maas M; Heijnen LA; Lambregts DM; Leijtens JW; Stassen LP; Breukink SO; Hoff C; Belgers EJ; Melenhorst J; Jansen R; Buijsen J; Hoofwijk TG; Beets-Tan RG; Beets GL
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27509881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is the Management of Rectal Cancer Using a Watch and Wait Approach Feasible, Safe and Effective in a Publicly Funded General Hospital?
    Kaul S; Rao C; Mane R; Tan KL; Khan AHA; Hussain MS; Shafi MA; Buettner F; Banerjee S; Boulton R; Bhargava A; Huang J; Hanson M; Raouf S; Ball S; Rajendran N
    Clin Oncol (R Coll Radiol); 2022 Jan; 34(1):e25-e34. PubMed ID: 34454807
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Organ preserving strategies for rectal cancer treatment].
    Vendrely V; Denost Q; Amestoy F; Célérier B; Smith D; Rullier A; Rullier É
    Cancer Radiother; 2015 Oct; 19(6-7):404-9. PubMed ID: 26278990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Organ Preservation in cT2N0 Rectal Cancer After Neoadjuvant Chemoradiation Therapy: The Impact of Radiation Therapy Dose-escalation and Consolidation Chemotherapy.
    Habr-Gama A; São Julião GP; Vailati BB; Sabbaga J; Aguilar PB; Fernandez LM; Araújo SEA; Perez RO
    Ann Surg; 2019 Jan; 269(1):102-107. PubMed ID: 28742703
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Particular aspects of treating rectal cancer: The watch and wait approach.
    Draghici DA; Stoian AR; Porojan VA; David OI; Bedereag Ş; Ciuhu AN; Haidar A; Creţoiu D; Condrat CE; Grigorean VT
    J Cancer Res Ther; 2023; 19(2):461-469. PubMed ID: 37006080
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term Oncological and Functional Outcomes of Chemoradiotherapy Followed by Organ-Sparing Transanal Endoscopic Microsurgery for Distal Rectal Cancer: The CARTS Study.
    Stijns RCH; de Graaf EJR; Punt CJA; Nagtegaal ID; Nuyttens JJME; van Meerten E; Tanis PJ; de Hingh IHJT; van der Schelling GP; Acherman Y; Leijtens JWA; Bremers AJA; Beets GL; Hoff C; Verhoef C; Marijnen CAM; de Wilt JHW;
    JAMA Surg; 2019 Jan; 154(1):47-54. PubMed ID: 30304338
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial.
    Garcia-Aguilar J; Renfro LA; Chow OS; Shi Q; Carrero XW; Lynn PB; Thomas CR; Chan E; Cataldo PA; Marcet JE; Medich DS; Johnson CS; Oommen SC; Wolff BG; Pigazzi A; McNevin SM; Pons RK; Bleday R
    Lancet Oncol; 2015 Nov; 16(15):1537-1546. PubMed ID: 26474521
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Application value of colonoscopic assessment in "watch and wait" strategy for mid-lower rectal cancer after neoadjuvant chemoradiotherapy].
    Li SJ; Wang L; Zhang XY; Li YH; Li ZW; Wu Q; Sun YS; Wu AW
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jul; 22(7):648-655. PubMed ID: 31302963
    [No Abstract]   [Full Text] [Related]  

  • 56. Watch and wait approach in rectal cancer: Current controversies and future directions.
    López-Campos F; Martín-Martín M; Fornell-Pérez R; García-Pérez JC; Die-Trill J; Fuentes-Mateos R; López-Durán S; Domínguez-Rullán J; Ferreiro R; Riquelme-Oliveira A; Hervás-Morón A; Couñago F
    World J Gastroenterol; 2020 Aug; 26(29):4218-4239. PubMed ID: 32848330
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer.
    Coraglio MF; Eleta MA; Kujaruk MR; Oviedo JH; Roca EL; Masciangioli GA; Mendez G; Iseas IS
    World J Surg Oncol; 2020 Nov; 18(1):313. PubMed ID: 33256819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Principle of surgical management for rectal cancer patients with complete clinical response after neoadjuvant therapy].
    Li XX; Luo DK
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):342-348. PubMed ID: 31054548
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Complete response after neoadjuvant therapy of rectal cancer: implications for surgery].
    Kastner C; Petritsch B; Reibetanz J; Germer CT; Wiegering A
    Chirurg; 2022 Feb; 93(2):144-151. PubMed ID: 34878582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis.
    Dossa F; Chesney TR; Acuna SA; Baxter NN
    Lancet Gastroenterol Hepatol; 2017 Jul; 2(7):501-513. PubMed ID: 28479372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.